Chimeric antigen receptor (CAR) T-cell therapy is a new, immune system-based cancer treatment that has garnered recent media attention. In a clinical trial, CAR T-cell treatment left no signs of tumors in 70% to 90% of children and adults with the aggressive blood cancer acute lymphocytic leukemia (ALL). ALL is almost always fatal, and the results observed with CAR T-cell treatment are nothing short of spectacular. Continue reading…
Editor’s note: This article is about results from an ongoing clinical trial—a research study with volunteer patients. The goal of the clinical trial is to test the effectiveness of a new non-Hodgkin lymphoma treatment called KTE-C19. So far, KTE-C19 has shown promising results, with eight out of 13 patients with advanced B-cell lymphoma experiencing complete remission and four experiencing partial remission.
“Kite Pharma (KITE) soared in after-hours trading on Monday after the company published successful data from its Phase 1-2a clinical trial of patients with aggressive non-Hodgkins lymphoma.
“Kite treated patients with its an anti-CD19 chimeric antigen receptor (CAR) T cell therapy called KTE-C19. Eight of 13 patients with Advanced B cell malignancies showed complete remissions, while four showed partial remissions. The total result was a 92% objective response rate.”